Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) Interest Expenses (2023 - 2026)

Tandem Diabetes Care filings provide 3 years of Interest Expenses readings, the most recent being $2.1 million for Q4 2025.

  • On a quarterly basis, Interest Expenses rose 11.56% to $2.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.9 million, a 6.64% increase, with the full-year FY2025 number at $7.9 million, up 6.64% from a year prior.
  • Interest Expenses hit $2.1 million in Q4 2025 for Tandem Diabetes Care, roughly flat from $2.1 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $4.8 million in Q3 2023 to a low of $1.6 million in Q2 2023.
  • Median Interest Expenses over the past 3 years was $1.9 million (2024), compared with a mean of $2.1 million.
  • The widest YoY moves for Interest Expenses: up 11.71% in 2024, down 61.47% in 2024.
  • Tandem Diabetes Care's Interest Expenses stood at $1.8 million in 2023, then grew by 3.16% to $1.9 million in 2024, then increased by 11.56% to $2.1 million in 2025.
  • The last three reported values for Interest Expenses were $2.1 million (Q4 2025), $2.1 million (Q3 2025), and $1.9 million (Q2 2025) per Business Quant data.